Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Tecan unveils AI partnerships and targets 20% EBITDA margin by 2028
Tecan presented its transformation program “Rewired” at the Morgan Stanley Global Healthcare Conference, aiming to boost margins and drive growth. Key strategic elements include partnerships with NVIDIA and Anthropic for AI-powered lab automation, along with portfolio adjustments and cost reductions. Tecan expects a currency-adjusted EBITDA margin of 20% by 2028, sees a recovery in the biopharma segment and weak demand from the academic sector. Operationally, management cited supply issues at Cavro, a partially completed CHF 120 million buyback program, and targeted M&A to strengthen the life-sciences portfolio. » Más en de.investing.com
Tecan to participate in Morgan Stanley Healthcare Conference in New York
Tecan will participate on 14 September 2026 in the 24th annual Morgan Stanley Healthcare Conference in New York and will be represented in a fireside chat. Participants are CEO Monica Manotas, CFO Camila Japur and Martin Brändle (SVP Corporate Communications & IR); a webcast will be streamed live on the investor overview at www.tecan.com and will be available for 120 days. » Más en finanzen.net
Tecan falls after H1 figures and cautious outlook
Tecan reported H1 2026 revenue of 427.5 million CHF and adjusted EBITDA of 64.5 million CHF (margin 15.1%), but showed weaker reported revenue, a sharply reduced operating cash flow of 17 million CHF and margin pressure. The share fell about 9% to $183.90 as investors reacted particularly to the decline in gross margins and continued transformation spending. Management kept the full-year guidance unchanged and expects low single-digit revenue growth and an adjusted EBITDA margin of 15.5–16.5%, now targeting the top end of the range. » Más en de.investing.com
Tecan announces conference call to present half-year results on 11 August
Tecan will explain the financial results for the first half of 2026 on Tuesday, 11 August 2026 at 09:00 CET in an English-language conference call; the press release will be published the same morning at 07:00 CET. The presentation will be available via telephone dial-in or webcast with synchronized slides; dial-in details will be published in advance. The full half-year report 2026 will be available from 11 August in the Investor Relations section of the company website. » Más en finanzen.net
Tecan (N) approves dividend of CHF 3.00 per share for 2025
At the annual general meeting on 15 April 2026, Tecan (N) approved a dividend of CHF 3.00 per share for 2025, totaling CHF 38.03 million. The dividend yield for 2025 is 2.33% based on the closing price on the AGM date of CHF 141.40; the stock is trading ex-dividend as of today. Over three years the share price is down around 64.98%. Analysts at FactSet expect the dividend to rise to CHF 3.40 by 2029. » Más en finanzen.net
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 463,16 M | - |
| Beneficio bruto | 157,02 M | - |
| Beneficio neto | 13,29 M | - |
| EBITDA | 50,64 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 3458,51 M € |
Número de acciones | 12,72 M |
Máximo/mínimo de 52 semanas | 298,98 € - 119,98 € |
Rentabilidad por dividendo | 1,21 % |
Dividendos TTM | 3,27 € |
Beta | 1,18 |
Ratio P/E | -27,42 |
Ratio PEG | 0,10 |
Ratio P/B | 2,79 |
Ratio P/S | 3,67 |
Perfil de la empresa
Tecan Group AG suministra instrumentos y soluciones de laboratorio para empresas farmacéuticas y de biotecnología, departamentos de investigación universitarios y laboratorios forenses y de diagnóstico. Opera a través de los segmentos Life Sciences Business y Partnering Business. La empresa ofrece manipulación de líquidos y automatización, lectores y lavadores de microplacas, consumibles, reactivos de NGS, inmunoensayos y microbodies, y software; Tecan Laberwax, una solución de automatización; Resolvex, una solución inteligente de preparación de muestras para su uso en genómica, biología sintética, descubrimiento de fármacos, química analítica, biología celular, ciencia de proteínas, mercados aplicados y soluciones ELISA. También desarrolla y fabrica componentes esenciales para fabricantes de instrumentos de laboratorio, que comprenden bombas de precisión, válvulas, brazos robóticos y software de desarrollo para la investigación en ciencias de la vida, el diagnóstico y otras diversas industrias; Synergence, una solución de automatización basada en plataformas; e instrumentos Freedom EVO y Fluent. La empresa opera en Suiza y otros países europeos, Norteamérica, Asia e internacionalmente. Tecan Group AG fue fundada en 1980 y tiene su sede en Männedorf, Suiza.
| Nombre | Tecan N |
| CEO | Monica Manotas |
| Sede | Männedorf,
zh Suiza |
| Sitio web | |
| Sector | Salud |
| Industria | Herramientas y servicios de ciencias de la vida |
| Salida a bolsa | 10/04/1995 |
| Empleados | 3244 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
SIX | TECN.SW |
London Stock Exchange | 0QLN.L |
Pnk | TCHBF |
London | 0QLN.L |
München | TEN.MU |